(+)-JQ1 target proteins, as excess small molecule (+)-JQ1 could outcompete them -resulting in loss of activity. By manipulating cellular localization through this mechanism, we pave the way for the development of more effective ASO therapeutics. The ability to actively augment the nuclear accumulation of ASOs, without increasing cellular toxicity, constitutes a significant advancement in the field. This advancement has the potential to improve therapeutic outcomes and expand the applicability of nucleic acid-based drugs.